Johnson & Johnson (J&J), a provider of eye health solutions, has expanded the availability of its TECNIS Odyssey intraocular lens (IOL) in the US.
Built on the TECNIS platform, TECNIS Odyssey IOL offers double the contrast in low-light conditions compared to PanOptix.
It utilises a technology to produce superior image quality, ensuring sharp vision even in challenging lighting. Its design also minimises visual disturbances, improving night-time visual quality.
Patients with the TECNIS Odyssey IOL have reported a high level of satisfaction with their vision without glasses, with 94% content with their overall vision.
The lens's freeform diffractive surface is crafted to provide seamless vision across near, intermediate, and far distances.
An impressive 96% of patients expressed satisfaction with their ability to read on smartphones or tablets, and 97% were happy with their distance vision.
Furthermore, the TECNIS Odyssey IOL is engineered to reduce night vision disturbances such as halos and glare, with 92% of patients satisfied with their night-time visibility.
J&J Company Vision Group chairman Peter Menziuso said: “TECNIS Odyssey patients have reported outstanding visual outcomes following surgery, which is why we are excited to announce we are expanding the roll-out across the US today.
“Cataract surgery gives patients a once-in-a-lifetime opportunity to improve their sight, and now with this advanced IOL, patients can see clearly at every distance, without the need for glasses.”
The TECNIS Odyssey IOL has not only been launched in the US but has also received approval from regulatory authorities in Japan, the European Union, Korea, Canada, Australia, Singapore and New Zealand.
Johnson & Johnson is also initiating the 'TECNIS Odyssey IOL Peer Connect' programme to encourage dialogue among healthcare professionals about the technology, leveraging insights from expert surgeons who have had early access to the lens.
In June this year, J&J concluded the acquisition of cardiovascular device developer Shockwave Medical in a deal valued at around $13.1bn.
